免疫检查点抑制剂在肺癌治疗中的研究进展

doi:10.3760/cma.j.cn371439-20201231-00135

摘要/Abstract

摘要：

近年来,免疫检查点抑制剂在肺癌的治疗中是一个里程碑式的突破。免疫检查点种类较多,包括程序性死亡蛋白-1(PD-1)、程序性死亡蛋白配体-1(PD-L1)、细胞毒性T淋巴细胞抗原4(CTLA-4)、杀伤细胞免疫球蛋白样受体(KIR)、T细胞免疫球蛋白和ITIM结构域蛋白(TIGIT)、细胞免疫球蛋白和黏蛋白3(TIM-3)等,与免疫治疗的疗效及耐药密切相关。PD-1/PD-L1抑制剂已被中国国家药品监督管理局及美国食品药品监督管理局批准用于肺癌的一线治疗,可延长患者的总生存期及无进展生存期。CTLA-4抑制剂或TIGIT抑制剂联合PD-1/PD-L1抑制剂的双免疫治疗亦取得良好疗效,但可能发生更严重的不良事件。KIR及TIM-3靶点与免疫治疗的耐药性密切相关。

关键词: 免疫疗法, 肺肿瘤, 免疫检查点抑制剂

Abstract:

In recent years, immune checkpoint inhibitors are a milestone in the treatment of lung cancer. There are many kinds of immune checkpoints, which are closely related to the efficacy and drug resis-tance of immunotherapy, including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), killer cell immunoglobulin-like receptor (KIR), T cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), etc. PD-1/PD-L1 inhibitors have been approved by China National Medical Products Administration and U.S. Food and Drug Administration for the first-line treatment of lung cancer, which can improve overall survival and progression-free survival of patients. The double immunotherapies of CTLA-4 inhibitors or TIGIT inhibitors combined with PD-1/PD-L1 inhibitors also achieve good results, however, more serious adverse events may occur.The KIR and TIM-3 targets are closely related to the drug resistance of immunotherapy.

Key words: Immunotherapy, Lung neoplasms, Immune checkpoint inhibitors

马骏, 张红颖, 吴艾平, 高广毅. 免疫检查点抑制剂在肺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(11): 683-687.

Ma Jun, Zhang Hongying, Wu Aiping, Gao Guangyi. Research progress of immune checkpoint inhibitors in the treatment of lung cancer[J]. Journal of International Oncology, 2021, 48(11): 683-687.

参考文献 38

[1]	Oberndorfer F, Müllauer L. Molecular pathology of lung cancer: current status and perspectives[J]. Curr Opin Oncol, 2018, 30(2):69-76. DOI: 10.1097/CCO.0000000000000429. doi: 10.1097/CCO.0000000000000429 pmid: 29251665
[2]	Ostoros G. Immunotherapy for lung cancer[J]. Magy Onkol, 2017, 61(2):153-157. pmid: 28585617
[3]	Jain P, Jain C, Vamsidhar V. Role of immune-checkpoint inhibitors in lung cancer[J]. Ther Adv Respir Dis, 2018, 12: 17534658177-50075. DOI: 10.1177/1753465817750075.
[4]	Reck M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer[J]. Immunotherapy, 2018, 10(2):93-105. DOI: 10.2217/imt-2017-0121. doi: 10.2217/imt-2017-0121
[5]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi: 10.1056/NEJMoa1606774
[6]	Wu YL, Zhang L, Fan Y, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study[J]. Int J Cancer, 2021, 148(9):2313-2320. DOI: 10.1002/ijc.33399. doi: 10.1002/ijc.v148.9
[7]	Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. doi: 10.1056/NEJMoa1801005
[8]	Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. doi: 10.1056/NEJMoa1810865
[9]	Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced NSCLC: pooled analysis from KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies[J]. Lung Cancer, 2019, 135:188-195. DOI: 10.1016/j.lungcan.2019.07.004. doi: 10.1016/j.lungcan.2019.07.004
[10]	Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial[J]. J Thorac Oncol, 2019, 14(5):867-875. DOI: 10.1016/j.jtho.2019.01.006. doi: 10.1016/j.jtho.2019.01.006
[11]	Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35):3924-3933. DOI: 10.1200/JCO.2017.74.3062. doi: 10.1200/JCO.2017.74.3062
[12]	Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305-314. DOI: 10.1016/S2213-2600(20)30365-9. doi: 10.1016/S2213-2600(20)30365-9
[13]	West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(6):924-937. DOI: 10.1016/S1470-2045(19)30167-6. doi: 10.1016/S1470-2045(19)30167-6
[14]	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. doi: 10.1056/NEJMoa1716948
[15]	Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. doi: 10.1056/NEJMoa1809064
[16]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. doi: S0140-6736(19)32222-6 pmid: 31590988
[17]	Zhang H, Shen J, Yi L, et al. Efficacy and safety of ipilimumab plus chemotherapy for advanced lung cancer: a systematic review and meta-analysis[J]. J Cancer, 2018, 9(23):4556-4567. DOI: 10.7150/jca.27368. doi: 10.7150/jca.27368
[18]	Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1):39. DOI: 10.1186/s40425-018-0349-3. doi: 10.1186/s40425-018-0349-3
[19]	Pinto JA, Raez LE, Oliveres H, et al. Current knowledge of ipilimumab and its use in treating non-small cell lung cancer[J]. Expert Opin Biol Ther, 2019, 19(6):509-515. DOI: 10.1080/14712598.2019.1610380. doi: 10.1080/14712598.2019.1610380
[20]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104. DOI: 10.1056/NEJMoa1801946. doi: 10.1056/NEJMoa1801946
[21]	Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort[J]. J Thorac Oncol, 2020, 15(3):426-435. DOI: 10.1016/j.jtho.2019.10.004. doi: S1556-0864(19)33531-2 pmid: 31629915
[22]	Trefny MP, Rothschild SI, Uhlenbrock F, et al. A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer[J]. Clin Cancer Res, 2019, 25(10):3026-3034. DOI: 10.1158/1078-0432.CCR-18-3041. doi: 10.1158/1078-0432.CCR-18-3041
[23]	He Y, Liu S, Mattei J, Bunn PA Jr, et al. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC[J]. Drug Des Devel Ther, 2018, 12:981-986.DOI: 10.2147/DDDT.S163304. doi: 10.2147/DDDT
[24]	Hu F, Wang W, Fang C, et al. TIGIT presents earlier expression dynamic than PD-1 in activated CD8⁺ T cells and is upregulated in non-small cell lung cancer patients[J]. Exp Cell Res, 2020, 396(1):112260. DOI: 10.1016/j.yexcr.2020.112260. doi: 10.1016/j.yexcr.2020.112260
[25]	Houssaini MS, Damou M, Ismaili N. Advances in the management of non-small cell lung cancer (NSCLC): a new practice changing data from ASCO 2020 annual meeting[J]. Cancer Treat Res Commun, 2020, 25:100239. DOI: 10.1016/j.ctarc.2020.100239. doi: 10.1016/j.ctarc.2020.100239 pmid: 33271494
[26]	Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape[J]. J Immunother Cancer, 2020, 8(1): e000911. DOI: 10.1136/jitc-2020-000911.
[27]	Jia K, He Y, Dziadziuszko R, et al. T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2019, 8(6):895-906. DOI: 10.21037/tlcr.2019.11.17. doi: 10.21037/tlcr
[28]	Limagne E, Richard C, Thibaudin M, et al. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients[J]. Oncoimmunology, 2019, 8(4): e1564505. DOI: 10.1080/2162402X.2018.1564505.
[29]	Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory functions of VISTA[J]. Immunol Rev, 2017, 276(1):66-79. DOI: 10.1111/imr.12525. doi: 10.1111/imr.2017.276.issue-1
[30]	Villarroel-Espindola F, Yu X, Datar I, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24(7):1562-1573. DOI: 10.1158/1078-0432.CCR-17-2542. doi: 10.1158/1078-0432.CCR-17-2542 pmid: 29203588
[31]	Hernandez-Martinez JM, Vergara E, Zatarain-Barrón ZL, et al. VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy[J]. J Thorac Dis, 2018, 10(12):6378-6382. DOI: 10.21037/jtd.2018.11.39. doi: 10.21037/jtd.2018.11.39 pmid: 30746169
[32]	Datar I, Sanmamed MF, Wang J, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis[J]. Clin Cancer Res, 2019, 25(15):4663-4673. DOI: 10.1158/1078-0432.CCR-18-4142. doi: 10.1158/1078-0432.CCR-18-4142 pmid: 31053602
[33]	Li X, Xu Z, Cui G, et al. BTLA expression in stage Ⅰ-Ⅲ non-small-cell lung cancer and its correlation with PD-1/PD-L1 and clinical outcomes[J]. Onco Targets Ther, 2020, 13:215-224. DOI: 10.2147/OTT.S232234. doi: 10.2147/OTT
[34]	Schoenfeld AJ, Rizvi H, Memon D, et al. Acquired resistance to PD-1 blockade in NSCLC[J]. J Clin Oncol, 2020, 38(15_suppl):9621. DOI: 10.1200/JCO.2020.38.15_suppl.9621. doi: 10.1200/JCO.2020.38.15_suppl.9621
[35]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. doi: 10.1016/S0140-6736(18)32409-7
[36]	Zhou C, Chen G, Huang Y, et al. A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced/metastatic non-squamous non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(10): S215-S216. DOI: 10.1016/j.jtho.2019.08.425.
[37]	Neal JW, Lim FL, Felip E, et al. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients pre-viously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study[EB/OL]. [2020-11-12].https://meetinglibrary.asco.org/record/184892/abstract .
[38]	Grohé C, Blau W, Gleiber W, et al. Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02-392455) [EB/OL].[2020-11-12].https://meetinglibrary.asco.org/record/184885/abstract .